mbrx20240104c

0001437749-24-000758.txt : 20240105 0001437749-24-000758.hdr.sgml : 20240105 20240105171426 ACCESSION NUMBER: 0001437749-24-000758 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20231229 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474671997 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 24517489 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20240104c_8k.htm FORM 8-K mbrx20240104c_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 29, 2023

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendment of Stock Plan

On December 29, 2023, the Board of Directors (the “Board”) of Moleculin Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the amendment of the Company’s 2015 Stock Plan, as amended (the “Plan”), subject to approval by the Company’s stockholders at its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), to increase the aggregate number of shares of Company common stock (the “Common Stock”) that may be issued pursuant to Awards (as defined in the Plan) by 1,100,000 shares (the “Plan Amendment”).

Granting of Performance Based Restricted Stock Units

On December 29, 2023, the Compensation Committee and Board approved the grant of performance-based restricted stock units (each, a “PSU”) under the Plan to the Company’s executive officers as follows: (i) Walter Klemp, Chief Executive Officer – 653,846 PSUs; (ii) Jonathan P. Foster, Chief Financial Officer – 287,692 PSUs; and (iii) Donald Picker, Chief Science Officer – 86,154 PSUs.

Each such PSU will only vest upon both:

(A) the approval of the Plan Amendment by the Company stockholders; and

(B) the first of the following to occur:

(a) a licensing transaction with a valuation, at the time, in excess of $150 million, which valuation shall be determined by the Board;

(b) the filing of a new drug application; or

(c) upon a Change in Control (as defined in the Plan), in each case subject to the respective executive officer’s continued service with us as of each such vesting date.

Entry into Employment Agreements

On January 4, 2024, the Company entered into amended and restated employment agreements with Messrs. Klemp and Foster and into a new employment agreement with Dr. Picker. These employments agreements standardize the employment language for all three officers.

These agreements do not increase the current salaries of these officers. Each of the agreements provides for compensation, as previously determined by the Compensation Committee after consulting with a compensation expert and comparing to similar companies, consisting of base salary, an annual bonus, and an annual option grant. For the compensation year ending May 31, 2024 (the Company’s compensation year runs from June 1 to May 31): (A) the base salaries for the above officers will be: (i) Mr. Klemp - $565,000; (ii) Mr. Foster - $405,000; and (iii) Dr. Picker - $340,000; and (B) the target annual bonus for the above officers will be: (i) Mr. Klemp – 66% of base salary; (ii) Mr. Foster – 49% of base salary; and (iii) Dr. Picker - 49% of base salary. The final determination on the amount, if any, of the annual bonus will be made by, and in the sole discretion of the Compensation Committee. The Compensation Committee will review the base salary and target annual bonus each year for adjustment, provided the base salaries may not be reduced.

Each of the agreements provides for an initial term of one year, which is automatically renewed for additional one-year terms unless either party chooses not to renew the agreement. If the officer’s employment is terminated at the Company’s election without “cause” (as defined in the agreement), which requires 90 days advance notice, or by the officer for “good reason” (as defined in the agreement), the officer shall be entitled to receive severance payments equal to twelve months of the officer’s base salary and 75% of the target annual bonus for the year in which such termination occurs. In addition, if the officer’s employment is terminated prior to the end of the term of the agreement by the Company without “cause” or by the officer for “good reason,” and such termination occurs within six months prior to a change in control or within twelve months after a change in control, the officer shall be entitled to receive, in addition to the severance discussed above, an additional twelve months of the officer’s base salary, and an additional 25% of the target annual bonus for the year in which such termination occurs. Each of the officers has agreed not to compete with the Company until twelve months after the termination of his employment.

The foregoing descriptions of the employment agreements are subject to and qualified in their entirety by reference to the full text of the employment agreements, copies of which is included as Exhibits 10.1, 10.2 and 10.3 hereto, respectively, the terms of which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

10.1	Amendment and Restated Employment Agreement between Moleculin Biotech, Inc. and Walter V. Klemp dated January 4, 2024
10.2	Amendment and Restated Employment Agreement between Moleculin Biotech, Inc. and Jonathan P. Foster dated January 4, 2024
10.3	Employment Agreement between Moleculin Biotech, Inc. and Donald Picker dated January 4, 2024

104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.


	Date:	January 5, 2024

	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster

EX-10.1 2 ex_612467.htm EXHIBIT 10.1 ex_612467.htm

Exhibit 10.1

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 4, 2024 (the “Effective Date”), by and between Moleculin Biotech, Inc., a Delaware corporation (the “Company”) having its principal place of business at 5300 Memorial Dr Ste 950, Houston, Texas, 77007, and Walter Klemp (“Executive”, and the Company and the Executive collectively referred to herein as the “Parties”) having his office at such location of his choosing.

WITNESSETH:

WHEREAS, the Executive previously served as the Company’s Chairman, President and Chief Executive Officer (“CEO”) pursuant to that certain Employment Agreement, dated as of October 13, 2016, between the Executive and the Company (the “First Employment Agreement”);

WHEREAS, the Company and Executive now both desire to amend and restate the First Employment Agreement in favor of this Agreement for Company to employ Executive as the Company’s CEO commencing as of the Effective Date, and the Parties desire to enter into this Agreement embodying the terms of such employment.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and promises of the Parties contained herein, the Parties, intending to be legally bound, hereby agree as follows:

1.	Title and Job Duties.

(a) Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as CEO. Executive shall report directly to the Board of Directors of the Company.

(b) Executive accepts such employment and agrees, during the term of his employment, to devote his business and professional time and energy to the Company, and agrees faithfully to perform his duties and responsibilities in an efficient, trustworthy and business‑like manner. Executive also agrees that the Board of Directors of the Company (the “Board”) shall determine from time to time such other duties as may be assigned to him. Executive agrees to carry out and abide by such directions of the Board.

(c) Without limiting the generality of the foregoing, Executive shall not, without the written approval of the Company, render services of a business or commercial nature on his own behalf or on behalf of any other person, firm, or corporation, whether for compensation or otherwise, during his employment hereunder. The foregoing limitation shall not apply to Executive’s involvement in associations, charities and service on another entity’s board of directors, provided such involvement does not interfere with Executives responsibilities (and as it pertains to any service on another entity’s board of directors, provided such action is pre-approved by the Company).

2.	Salary and Additional Compensation.

(a) Base Salary. The Company shall pay to Executive an annual base salary (“Base Salary”) of five hundred and sixty-five thousand dollars ($565,000) in accordance with the Company’s normal payroll procedures, effective as of the Effective Date. The Compensation Committee shall review the Executive’s Base Salary no less than annually, beginning in June 2024,and may increase (but not decrease) such Base Salary during the term of this Agreement.

(b) Annual Bonus. Commencing with the compensation year ending May 31, 2024, Executive will be entitled to receive an annual cash bonus (the “Annual Bonus”), payable with respect to each compensation year of the Term subsequent to the issuance of the Company’s final audited financial statements for such year. The target Annual Bonus for the year ending May 31, 2024 will be sixty-six (66%) of Base Salary. The final determination on the amount, if any, of the Annual Bonus will be made by, and in the sole discretion of the Compensation Committee of the Board of Directors of the Company (the “Board”) (or the Board, if such committee has not been established or has been dissolved), based on criteria established by the Compensation Committee of the Board (or the Board, if such committee has not been established or has been dissolved). For the compensation year (the “compensation year” shall initially be from June 1 to May 31, and is subject to change by the Company) in which Executive commences employment with the Company, Executive will be entitled to receive an Annual Bonus which is prorated based on the number of days from the Effective Date until the end of the fiscal year divided by 365.

(c) Annual Option Grant. For each compensation year during the Term commencing with the compensation year commencing June 1, 2023, Executive will be entitled to receive an annual option grant under the Moleculin Biotech, Inc. 2015 Stock Plan, or any future stock plans approved by the Company’s stockholders (the “Stock Plan”) (the “Annual Grant”), subject to the availability of shares of common stock under the Stock Plan, within ninety (90) days of the completion of such compensation year, provided Executive is employed by the Company on such date. The final determination on the amount, if any, of the Annual Grant will be made by, and in the sole discretion of, the Compensation Committee (or the Board, if such committee has not been formed or has been dissolved), based on goals and objectives approved by the Compensation Committee of the Board (or the Board, if such committee has not been formed or has been dissolved). Unless otherwise determined by the Compensation Committee (or the Board, if such committee has not been formed or has been dissolved), the Annual Grant shall have a term of ten years and shall vest in four (4) equal installments on each of the succeeding four anniversary dates of the date of grant, provided Executive remains continuously employed by Company through each such vesting date. The Annual Grant shall be made pursuant to the Stock Plan, and shall in all respects be subject to the terms and conditions of such plan.

(d) Expenses. In accordance with Company policy, the Company shall reimburse Executive for all reasonable association fees, professional related expenses (certifications, licenses and continuing professional education) and business expenses properly and necessarily incurred and paid by Executive in the performance of his duties under this Agreement, including without limitation all travel expenses to and from his designated office as set forth in the opening paragraph of this Agreement, upon his presentment of detailed receipts in the form required by the Company’s policy. Notwithstanding the foregoing, all expenses must be promptly submitted for reimbursement by the Executive, and in no event shall any reimbursement be paid by the Company after the end of the year following the year in which the expense is incurred by the Executive.

3. Benefits.

(a) Vacation and Sick Leave. Executive shall be entitled to a minimum of four (4) weeks of vacation per year and six (6) days of sick leave per year, which shall accrue at a pro rata rate per pay period. Vacation must be taken in the year in which it accrues.

(b) Health Insurance and Other Plans. Executive shall be eligible to participate in the Company’s medical, dental and other employee benefit programs, if any, that are provided by the Company for its employees at Executive’s level in accordance with the provisions of any such plans, as the same may be in effect from time to time.

4. Term. The term of employment under this Agreement (the “Term) shall initially be for a one-year period commencing on the Effective Date (unless ending earlier pursuant to Section 5) and shall be automatically extended for additional consecutive twelve (12)-month periods on the anniversary of the Effective Date and each subsequent anniversary thereof, unless and until the Company or Executive provides written notice to the other party not less than ninety (90) days before such anniversary date that such party is electing not to extend the Term, in which case the Term shall end at the expiration of the Term as last extended, unless sooner terminated as set forth below. Following any such notice by the Company of its election not to extend the Term, Executive may terminate his employment at any time prior to the expiration of the Term by giving written notice to the Company at least thirty (30) days prior to the effective date of termination, and upon the earlier of such effective date of termination or the expiration of the Term, Executive shall be entitled to receive the same severance benefits as are provided upon a termination of employment by the Company without Cause as described in Section 6(a) and Section 6(d). The Term will run year to year until terminated.

5. Termination.

(a) Termination at the Company’s Election.

(i) For Cause. At the election of the Company, Executive’s employment may be terminated at any time for Cause (as defined below) upon written notice to Executive given pursuant to Section 11 of this Agreement. For purposes of this Agreement, “Cause” for termination shall mean that Executive: (A) pleads “guilty” or “no contest” to, or is convicted of an act which is defined as a felony under federal or state law, or is indicted or formally charged with acts involving criminal fraud or embezzlement; (B) in carrying out his duties, engages in conduct that constitutes gross negligence or willful misconduct; (C) engages in substantiated fraud, misappropriation or embezzlement against the Company; (D) engages in any inappropriate or improper conduct that causes material harm to the reputation of the Company; or (E) materially breaches any term of this Agreement. With respect to subsection (E) of this section, to the extent such material breach may be cured, the Company shall provide Executive with written notice of the material breach and Executive shall have ten (10) days to cure such breach.

(ii) Upon Disability, Death or Without Cause. At the election of the Company, Executive’s employment may be terminated: (A) should Executive have a physical or mental impairment that substantially limits a major life activity and Executive is unable to perform the essential functions of his job with or without reasonable accommodation (“Disability”); (B) upon Executive’s death; or (C) with ninety (90) days prior written notice, at any time Without Cause for any or no reason.

(b) Termination at Executive’s Election; Good Reason Termination. Notwithstanding anything contained elsewhere in this Agreement to the contrary, Executive may terminate his employment hereunder at any time and for any reason, upon thirty (30) days’ prior written notice given pursuant to Section 11 of this Agreement (“Voluntary Resignation”), provided that upon notice of resignation, the Company may terminate Executive’s employment immediately and pay Executive thirty (30) days’ Base Salary in lieu of notice. Furthermore, the Executive may terminate this Agreement for “Good Reason,” which shall be deemed to exist: (i) if the Company’s Board of Directors or that of any successor entity of Company, fails to appoint or reappoint the Executive or removes the Executive as the CEO of the Company; (ii) if Executive is assigned any duties materially inconsistent with the duties or responsibilities of the CEO of the Company as contemplated by this Agreement or any other action by the Company that results in a material diminution in such position, authority, duties, or responsibilities, excluding an isolated, insubstantial, and inadvertent action not taken in bad faith; or (iii) a material breach by the Company of this Agreement. Good Reason shall not exist hereunder unless the Executive provides notice in writing to the Company of the existence of a condition described above within a period not to exceed ninety (90) days of the initial existence of the condition, and with respect to subsection (iii) of this section, to the extent such material breach may be cured, the Company does not remedy the condition within thirty (30) days of receipt of such notice and Executive terminates employment for such notice within thirty (30) days after such cure period has expired if the breach was curable and has not been remedied.

(c) Termination in General. If Executive’s employment with the Company terminates for any reason, the Company will pay or provide to Executive: (i) any unpaid Salary through the date of employment termination, (ii) any unpaid Annual Bonus for the compensation year prior to the fiscal year in which the termination occurs (payable at the time the bonuses are paid to employees generally), (iii) any accrued but unused vacation or paid time off in accordance with the Company’s policy, (iv) reimbursement for any unreimbursed business expenses incurred through the termination date, to the extent reimbursable in accordance with Section 2(d), and (v) all other payments or benefits (if any) to which Executive is entitled under the terms of any benefit plan or arrangement.

6. Severance.

(a) Subject to Section 6(b) below, if Executive’s employment is terminated prior to the end of the Term by the Company without Cause or by Executive for Good Reason, Executive shall be entitled to receive a severance payment equal to (i) 12 months of Executive's Base Salary, and (ii) 75% of the target Annual Bonus for the compensation year in which such termination occurs. Such severance payment shall be paid in 12 equal monthly payments commencing with the first payroll following such termination, provided the Executive has executed and delivered to the Company, and has not revoked a general release of the Company, its parents, subsidiaries and affiliates and each of its officers, directors, employees, agents, successors and assigns, and such other persons and/or entities as the Company may determine, in a form reasonably acceptable to the Company. Such general release shall be delivered on or about the date of termination and must be executed within fifty-five (55) days of termination.

(b) If Executive’s employment is terminated prior to the end of the Term by the Company without Cause or by Executive for Good Reason, and such termination occurs within six (6) months prior to a Change in Control or within twelve (12) months after the Change in Control, Executive shall be entitled to receive, in addition to any severance pursuant to Section 6(a) above, an additional 12 months of Executive’s Base Salary, and an additional 25% of the target Annual bonus.

(c) Notwithstanding the foregoing, (i) any payment(s) of “nonqualified deferred compensation” (within the meaning of Section 409A of the Code and the regulations and official guidance issued thereunder (“Section 409A”)) that is/are required to be made to Executive hereunder as a “specified employee” (as defined under Section 409A) as a result of such employee’s “separation from service” (within the meaning of Section 409A) shall be delayed for the first six (6) months following such separation from service (or, if earlier, the date of death of the specified employee) and shall instead be paid upon expiration of such six (6) month delay period; and (ii) for purposes of any such payment that is subject to Section 409A, if the Executive’s termination of employment triggers the payment of “nonqualified deferred compensation” hereunder, then the Executive will not be deemed to have terminated employment until the Executive incurs a “separation from service” within the meaning of Section 409A.

(d) If Executive's employment is terminated prior to the end of the Term by the Company without Cause or by Executive for Good Reason, and if Executive is eligible for and elects to continue to participate in the Company’s medical and dental benefit programs pursuant to COBRA, the Company will continue to pay the same portion of Executive's medical and dental insurance premiums under COBRA as during active employment (for Executive and eligible spouse and dependents) until the earlier of: (1) 12 months from Executive's cessation from employment; or (2) the date Executive is eligible for medical and/or dental insurance benefits from another employer.

7. Confidentiality Agreement.

(a) Executive understands that during the Term he may have access to unpublished and otherwise confidential information both of a technical and non-technical nature, relating to the business of the Company and any of its parents, subsidiaries, divisions, affiliates (collectively, “Affiliated Entities”), or clients, including without limitation any of their actual or anticipated business, research or development, any of their technology or the implementation or exploitation thereof, including without limitation information Executive and others have collected, obtained or created, information pertaining to patent formulations, vendors, prices, costs, materials, processes, codes, material results, technology, system designs, system specifications, materials of construction, trade secrets and equipment designs, including information disclosed to the Company by others under agreements to hold such information confidential (collectively, the “Confidential Information”). Executive agrees to observe all Company policies and procedures concerning such Confidential Information. Executive further agrees not to disclose or use, either during his employment or at any time thereafter, any Confidential Information for any purpose, including without limitation any competitive purpose, unless authorized to do so by the Company in writing, except that he may disclose and use such information when necessary in the performance of his duties for the Company. Executive’s obligations under this Agreement will continue with respect to Confidential Information, whether or not his employment is terminated, until such information becomes generally available from public sources through no action of Executive. Nothing herein shall prohibit Executive from (i) reporting a suspected violation of law to any governmental or regulatory agency and cooperating with such agency, or from receiving a monetary recovery for information provided to such agency, (ii) testifying truthfully under oath pursuant to subpoena or other legal process or (iii) making disclosures that are otherwise protected under applicable law or regulation. However, if Executive is required by subpoena or other legal process to disclose Confidential Information, Executive first shall notify the Company promptly upon receipt of the subpoena or other notice and allow the Company the opportunity to obtain a protective order or other appropriate remedy, unless otherwise prohibited by law.

(b) During Executive’s employment, upon the Company’s request, or upon the termination of his employment for any reason, Executive will promptly deliver to the Company all documents, records, files, notebooks, manuals, letters, notes, reports, customer and supplier lists, cost and profit data, e-mail, apparatus, computers, cell phones, tablets, hardware, software, drawings, and any other material of the Company or any of its Affiliated Entities or clients, including all materials pertaining to Confidential Information developed by Executive or others, and all copies of such materials, whether of a technical, business or fiscal nature, whether on the hard drive of a laptop or desktop computer, in hard copy, disk or any other format, which are in Executive’s possession, custody or control.

(c) Executive will promptly disclose to the Company any idea, invention, discovery or improvement, whether patentable or not (“Creations”), conceived or made by him alone or with others at any time during his employment. Executive agrees that the Company owns all such Creations, conceived or made by Executive alone or with others at any time during his employment, and Executive hereby assigns and agrees to assign to the Company all rights he has or may acquire therein and agrees to execute any and all applications, assignments and other instruments relating thereto which the Company deems necessary or desirable. These obligations shall continue beyond the termination of his employment with respect to Creations and derivatives of such Creations conceived or made during his employment with the Company. Executive understands that the obligation to assign Creations to the Company shall not apply to any Creation which is developed entirely on his own time without using any of the Company’s equipment, supplies, facilities, and/or Confidential Information unless such Creation (a) relates in any way to the business or to the current or anticipated research or development of the Company or any of its Affiliated Entities; or (b) results in any way from his work at the Company.

(d) Executive will not assert any rights to any invention, discovery, idea or improvement relating to the business of the Company or any of its Affiliated Entities or to his duties hereunder as having been made or acquired by Executive prior to his work for the Company, except for the matters, if any, described in Appendix A to this Agreement.

(e) During the Term, if Executive incorporates into a product or process of the Company or any of its Affiliated Entities anything listed or described in Appendix A, the Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to grant and authorize sublicenses) to make, have made, modify, use, sell, offer to sell, import, reproduce, distribute, publish, prepare derivative works of, display, perform publicly and by means of digital audio transmission and otherwise exploit as part of or in connection with any product, process or machine.

(f) Executive agrees to cooperate fully with the Company, both during and up to twelve (12) months after his employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents, trademarks and other intellectual property rights (both in the United States and foreign countries) relating to such Creations. Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Creations. Executive further agrees that if the Company is unable, after reasonable effort, to secure Executive’s signature on any such papers, any officer of the Company shall be entitled to execute such papers as his agent and attorney-in-fact and Executive hereby irrevocably designates and appoints each officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Creations, under the conditions described in this paragraph.

8. Non-solicitation; non-competition. (a) Executive agrees that, during the Term and until 12 months after the termination of his employment, Executive will not, directly or indirectly, including on behalf of any person, firm or other entity, employ or actively solicit for employment any employee of the Company or any of its Affiliated Entities, or induce any such employee to terminate his or his employment with the Company or any of its Affiliated Entities.

(b) Executive further agrees that, during the Term and until 12 months after the termination of his employment, Executive will not, directly or indirectly, including on behalf of any person, firm or other entity, without the express written consent of an authorized representative of the Company, (i) perform services within the Territory (as defined below) for any Competing Business (as defined below), whether as an employee, consultant, agent, contractor or in any other capacity, (ii) hold office as an officer or director or like position in any Competing Business, or (iii) request any present or future customers or suppliers of the Company or any of its Affiliated Entities to curtail or cancel their business with the Company or any of its Affiliated Entities. These obligations in (a) and (b) will continue for the specified period regardless of whether the termination of Executive’s employment was voluntary or involuntary or with or without Cause or for any other reason.

(c) “Competing Business” means any corporation, partnership or other entity or person (other than the Company) which is engaged (a) in the development, manufacture, marketing, distribution or sale of, or research directed to the development, manufacture, marketing, distribution or sale of, competing drug products for cancers and viruses or (b) in any other business activity carried on or planned to be carried on by the Company or any of its Affiliated Entities during the Term.

(d) “Territory” shall mean within any state or foreign jurisdiction in which the Company or any Affiliated Entities of the Company is then providing services or products or marketing its services or products (or engaged in active discussions to provide such services).

(e) Executive agrees that in the event a court determines the length of time or the geographic area or activities prohibited under this Section 8 are too restrictive to be enforceable, the court shall reduce the scope of the restriction to the extent necessary to make the restriction enforceable. In furtherance and not in limitation of the foregoing, the Company and the Executive each intend that the covenants contained in this Section 8 shall be deemed to be a series of separate covenants, one for each and every state, territory or jurisdiction of the United States and any foreign country set forth therein. If, in any judicial proceeding, a court shall refuse to enforce any of such separate covenants, then such unenforceable covenants shall be deemed eliminated from the provisions hereof for the purpose of such proceedings to the extent necessary to permit the remaining separate covenants to be enforced in such proceedings.

9. Representation and Warranty. The Executive hereby acknowledges and represents that he has had the opportunity to consult with legal counsel regarding his rights and obligations under this Agreement and that he fully understands the terms and conditions contained herein. Executive represents and warrants that Executive has provided the Company a true and correct copy of any agreements that purport: (a) to limit Executive’s right to be employed by the Company; (b) to prohibit Executive from engaging in any activities on behalf of the Company; or (c) to restrict Executive’s right to use or disclose any information while employed by the Company. Executive further represents and warrants that Executive will not use on the Company’s behalf any information, materials, data or documents belonging to a third party that are not generally available to the public, unless Executive has obtained written authorization to do so from the third party and provided such authorization to the Company. In the course of Executive’s employment with the Company, Executive is not to breach any obligation of confidentiality that Executive has with third parties, and Executive agrees to fulfill all such obligations during Executive’s employment with the Company. Executive further agrees not to disclose to the Company or use while working for the Company any trade secrets belonging to a third party.

10. Injunctive Relief. Without limiting the remedies available to the Company, Executive acknowledges that a breach of any of the covenants contained in Sections 7 and 8 above may result in material irreparable injury to the Company for which there is no adequate remedy at law, that it will not be possible to measure precisely damages for such injuries and that, in the event of such a breach or threat thereof, the Company shall be entitled, without the requirement to post bond or other security, to obtain a temporary restraining order and/or injunction restraining Executive from engaging in activities prohibited by this Agreement or such other relief as may be required to specifically enforce any of the covenants in Sections 7 and 8 of this Agreement.

11. Notice. Any notice or other communication required or permitted to be given to the Parties shall be deemed to have been given if either personally delivered, or if sent for next-day delivery by nationally recognized overnight courier, and addressed as follows:

If to Executive, to:

90 Woodbury Ct
Coldspring, TX 77331-3289

If to the Company, to:

Moleculin Biotech, Inc.

5300 Memorial Dr Ste 950

Houston, Texas, 77007

Attention: Legal

With a copy to:

Cavas S. Pavri, Esq.

ArentFox Schiff LLP

1717 K Street, NW

Washington, DC 20006

12. Severability. If any provision of this Agreement is declared void or unenforceable by a court of competent jurisdiction, all other provisions shall nonetheless remain in full force and effect.

13. Withholding. The Company may withhold from any payment that it is required to make under this Agreement amounts sufficient to satisfy applicable withholding requirements under any federal, state or local law.

14. Indemnification. The Company shall purchase and maintain director and officer liability insurance on such terms and providing such coverage as the Board determines is appropriate from time-to-time, and the Executive shall be covered by such insurance, pursuant to the terms of the applicable plan(s) and policy(ies), to the same extent as similarly situated officers and directors of the Company. The Company shall enter into an agreement to indemnify the Executive which agreement shall survive upon termination of this Agreement for any reason.

15. Clawback and Recoupment Policy. The Executive acknowledges and agrees that the compensation paid pursuant to this Agreement shall be subject to any reasonable clawback or recoupment policy, which the Company may put in force to comply with any regulations and exchange standards, that the Company may have in effect from time to time.

16. Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Texas, without regard to the conflict of laws provisions thereof. Any action, suit or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be submitted to the exclusive jurisdiction of any state or federal court in Harris County, Texas.

17. Waiver. The waiver by either Party of a breach of any provision of this Agreement shall not be or be construed as a waiver of any subsequent breach. The failure of a Party to insist upon strict adherence to any provision of this Agreement on one or more occasions shall not be considered a waiver or deprive that Party of the right thereafter to insist upon strict adherence to that provision or any other provision of this Agreement. Any such waiver must be in writing, signed by the Party against whom such waiver is to be enforced.

18. Assignment. This Agreement is a personal contract and Executive may not sell, transfer, assign, pledge or hypothecate his rights, interests and obligations hereunder. Except as otherwise herein expressly provided, this Agreement shall be binding upon and shall inure to the benefit of Executive and his personal representatives and shall inure to the benefit of and be binding upon the Company and its successors and assigns, including without limitation, any corporation or other entity into which the Company is merged or which acquires all or substantially all of the assets of the Company.

19. Entire Agreement. This Agreement (together with Appendix A hereto) embodies all of the representations, warranties, covenants, understandings and agreements between the Parties relating to Executive’s employment with the Company. No other representations, warranties, covenants, understandings, or agreements exist between the Parties relating to Executive’s employment. This Agreement shall supersede all prior agreements, written or oral, relating to Executive’s employment. This Agreement may not be amended or modified except by a writing signed by the Parties.

[Signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date first written above.

	MOLECULIN BIOTECH, INC.



	By:	/s/ Jonathan P. Foster
	Name: Jonathan P. Foster Title: EVP & CFO
Agreed to and Accepted:


/s/ Walter V. Klemp
Walter Klemp
Date: January 4, 2024

Appendix A

None.

EX-10.2 3 ex_612468.htm EXHIBIT 10.2 ex_612468.htm

Exhibit 10.2

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 4, 2024 (the “Effective Date”), by and between Moleculin Biotech, Inc., a Delaware corporation (the “Company”) having its principal place of business at 5300 Memorial Dr Ste 950, Houston, Texas, 77007, and Jonathan Foster (“Executive”, and the Company and the Executive collectively referred to herein as the “Parties”) having his office at such location of his choosing.

WITNESSETH:

WHEREAS, the Executive previously served as the Company’s Executive Vice President and Chief Financial Officer (“CFO”) pursuant to that certain Employment Agreement, dated as of August 19, 2016, between the Executive and the Company (the “First Employment Agreement”);

WHEREAS, the Company and Executive now both desire to amend and restate the First Employment Agreement in favor of this Agreement for Company to employ Executive as the Company’s CFO commencing as of the Effective Date, and the Parties desire to enter into this Agreement embodying the terms of such employment.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and promises of the Parties contained herein, the Parties, intending to be legally bound, hereby agree as follows:

1. Title and Job Duties.

(a) Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as CFO. Executive shall report directly to the Board of Directors of the Company.

2. Salary and Additional Compensation.

(a) Base Salary. The Company shall pay to Executive an annual base salary (“Base Salary”) of four hundred and five thousand ($405,000) in accordance with the Company’s normal payroll procedures, effective as of the Effective Date. The Compensation Committee shall review the Executive’s Base Salary no less than annually, beginning in June 2024, and may increase (but not decrease) such Base Salary during the term of this Agreement.

(b) Annual Bonus. Commencing with the compensation year ending May 31, 2024, Executive will be entitled to receive an annual cash bonus (the “Annual Bonus”), payable with respect to each compensation year of the Term subsequent to the issuance of the Company’s final audited financial statements for such year. The target Annual Bonus for the year ending May 31, 2024 will be forty-nine percent (49%) of Base Salary. The final determination on the amount, if any, of the Annual Bonus will be made by, and in the sole discretion of the Compensation Committee of the Board of Directors of the Company (the “Board”) (or the Board, if such committee has not been established or has been dissolved), based on criteria established by the Compensation Committee of the Board (or the Board, if such committee has not been established or has been dissolved). For the compensation year (the “compensation year” shall initially be from June 1 to May 31, and is subject to change by the Company) in which Executive commences employment with the Company, Executive will be entitled to receive an Annual Bonus which is prorated based on the number of days from the Effective Date until the end of the fiscal year divided by 365.

3. Benefits.

5. Termination.

(a) Termination at the Company’s Election.

(b) Termination at Executive’s Election; Good Reason Termination. Notwithstanding anything contained elsewhere in this Agreement to the contrary, Executive may terminate his employment hereunder at any time and for any reason, upon thirty (30) days’ prior written notice given pursuant to Section 11 of this Agreement (“Voluntary Resignation”), provided that upon notice of resignation, the Company may terminate Executive’s employment immediately and pay Executive thirty (30) days’ Base Salary in lieu of notice. Furthermore, the Executive may terminate this Agreement for “Good Reason,” which shall be deemed to exist: (i) if the Company’s Board of Directors or that of any successor entity of Company, fails to appoint or reappoint the Executive or removes the Executive as the CFO of the Company; (ii) if Executive is assigned any duties materially inconsistent with the duties or responsibilities of the CFO of the Company as contemplated by this Agreement or any other action by the Company that results in a material diminution in such position, authority, duties, or responsibilities, excluding an isolated, insubstantial, and inadvertent action not taken in bad faith; or (iii) a material breach by the Company of this Agreement. Good Reason shall not exist hereunder unless the Executive provides notice in writing to the Company of the existence of a condition described above within a period not to exceed ninety (90) days of the initial existence of the condition, and with respect to subsection (iii) of this section, to the extent such material breach may be cured, the Company does not remedy the condition within thirty (30) days of receipt of such notice and Executive terminates employment for such notice within thirty (30) days after such cure period has expired if the breach was curable and has not been remedied.

6. Severance.

7. Confidentiality Agreement.

If to Executive, to:

123 Bitternut Rd

Fernandina Beach, FL 32034

If to the Company, to:

Moleculin Biotech, Inc.

5300 Memorial Dr Ste 950

Houston, Texas, 77007

Attention: Legal

With a copy to:

Cavas S. Pavri, Esq.

ArentFox Schiff LLP

1717 K Street, NW

Washington, DC 20006

12. Severability. If any provision of this Agreement is declared void or unenforceable by a court of competent jurisdiction, all other provisions shall nonetheless remain in full force and effect.

[Signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date first written above.

	MOLECULIN BIOTECH, INC.



	By:	/s/ Walter V. Klemp
	Name: Walter Klemp Title: CEO
Agreed to and Accepted:


/s/ Jonathan P. Foster
Jonathan P. Foster
Date: January 4, 2024

Appendix A

None.

EX-10.3 4 ex_612469.htm EXHIBIT 10.3 ex_612469.htm

Exhibit 10.3

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 4, 2024 (the “Effective Date”), by and between Moleculin Biotech, Inc., a Delaware corporation (the “Company”) having its principal place of business at 5300 Memorial Dr Ste 950, Houston, Texas, 77007, and Donald Picker (“Executive”, and the Company and the Executive collectively referred to herein as the “Parties”) having his office at such location of his choosing.

WITNESSETH:

WHEREAS, the Company desires to hire Executive and to employ him as the Company’s Chief Science Officer (“CSO”) commencing on the Effective Date, and the Parties desire to enter into this Agreement embodying the terms of such employment;

NOW, THEREFORE, in consideration of the premises and the mutual covenants and promises of the Parties contained herein, the Parties, intending to be legally bound, hereby agree as follows:

1. Title and Job Duties.

(a) Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as CSO. Executive shall report directly to the Chief Executive Officer.

2. Salary and Additional Compensation.

(a) Base Salary. The Company shall pay to Executive an annual base salary (“Base Salary”) of three hundred and forty thousand dollars ($340,000) in accordance with the Company’s normal payroll procedures, effective as of the Effective Date. The Compensation Committee shall review the Executive’s Base Salary no less than annually, beginning in June 2024, and may increase (but not decrease) such Base Salary during the term of this Agreement, unless mutually agreed upon by the Parties.

(b) Annual Bonus. Commencing with the compensation year ending May 31, 2024, Executive will be entitled to receive an annual cash bonus (the “Annual Bonus”), payable with respect to each compensation year of the Term subsequent to the issuance of the Company’s final audited financial statements for such year. The target Annual Bonus for the year ending May 31, 2024 will be forty-seven percent (47%) of Base Salary. The final determination on the amount, if any, of the Annual Bonus will be made by, and in the sole discretion of the Compensation Committee of the Board of Directors of the Company (the “Board”) (or the Board, if such committee has not been established or has been dissolved), based on criteria established by the Compensation Committee of the Board (or the Board, if such committee has not been established or has been dissolved). For the compensation year (the “compensation year” shall initially be from June 1 to May 31, and is subject to change by the Company) in which Executive commences employment with the Company, Executive will be entitled to receive an Annual Bonus which is prorated based on the number of days from the Effective Date until the end of the fiscal year divided by 365.

3. Benefits.

5. Termination.

(a) Termination at the Company’s Election.

(b) Termination at Executive’s Election; Good Reason Termination. Notwithstanding anything contained elsewhere in this Agreement to the contrary, Executive may terminate his employment hereunder at any time and for any reason, upon thirty (30) days’ prior written notice given pursuant to Section 11 of this Agreement (“Voluntary Resignation”), provided that upon notice of resignation, the Company may terminate Executive’s employment immediately and pay Executive thirty (30) days’ Base Salary in lieu of notice. Furthermore, the Executive may terminate this Agreement for “Good Reason,” which shall be deemed to exist: (i) if the Company’s Board of Directors or that of any successor entity of Company, fails to appoint or reappoint the Executive or removes the Executive as the CSO of the Company; (ii) if Executive is assigned any duties materially inconsistent with the duties or responsibilities of the CSO of the Company as contemplated by this Agreement or any other action by the Company that results in a material diminution in such position, authority, duties, or responsibilities, excluding an isolated, insubstantial, and inadvertent action not taken in bad faith; or (iii) a material breach by the Company of this Agreement. Good Reason shall not exist hereunder unless the Executive provides notice in writing to the Company of the existence of a condition described above within a period not to exceed ninety (90) days of the initial existence of the condition, and with respect to subsection (iii) of this section, to the extent such material breach may be cured, the Company does not remedy the condition within thirty (30) days of receipt of such notice and Executive terminates employment for such notice within thirty (30) days after such cure period has expired if the breach was curable and has not been remedied.

6. Severance.

7. Confidentiality Agreement.

If to Executive, to:

11717 Goldenrod Ave
Bradenton, FL 34212

If to the Company, to:

Moleculin Biotech, Inc.

5300 Memorial Dr Ste 950

Houston, Texas, 77007

Attention: Legal

With a copy to:

Cavas S. Pavri, Esq.

ArentFox Schiff LLP

1717 K Street, NW

Washington, DC 20006

12. Severability. If any provision of this Agreement is declared void or unenforceable by a court of competent jurisdiction, all other provisions shall nonetheless remain in full force and effect.

[Signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered on the date first written above.

	MOLECULIN BIOTECH, INC.



	By:	/s/ Jonathan P. Foster
	Name: Jonathan P. Foster Title: EVP & CFO


Agreed to and Accepted:


/s/ Donald Picker
Donald Picker

Date: January 4, 2024

Appendix A

None.

EX-101.SCH 5 mbrx-20231229.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 6 mbrx-20231229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 mbrx-20231229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 8 mbrx-20231229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 mbrx20240104c_8kimg001.jpg begin 644 mbrx20240104c_8kimg001.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Dec. 29, 2023
Document Information [Line Items]
Entity, Registrant Name	MOLECULIN BIOTECH, INC.
Document, Type	8-K
Document, Period End Date	Dec. 29, 2023
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-37758
Entity, Tax Identification Number	47-4671997
Entity, Address, Address Line One	5300 Memorial Drive
Entity, Address, Address Line Two	Suite 950
Entity, Address, City or Town	Houston
Entity, Address, State or Province	TX
Entity, Address, Postal Zip Code	77007
City Area Code	713
Local Phone Number	300-5160
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	false
Title of 12(b) Security	Common Stock
Trading Symbol	MBRX
Security Exchange Name	NASDAQ
Amendment Flag	false
Entity, Central Index Key	0001659617

XML 11 mbrx20240104c_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2023-12-29 2023-12-29 false 0001659617 8-K 2023-12-29 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive Suite 950 Houston TX 77007 713 300-5160 false false false false false Common Stock MBRX NASDAQ EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20231229/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx-20231229.xsd mbrx-20231229_def.xml mbrx-20231229_lab.xml mbrx-20231229_pre.xml mbrx20240104c_8k.htm mbrx20240104c_8kimg001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mbrx20240104c_8k.htm": { "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20231229", "dts": { "schema": { "local": [ "mbrx-20231229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "mbrx-20231229_def.xml" ] }, "labelLink": { "local": [ "mbrx-20231229_lab.xml" ] }, "presentationLink": { "local": [ "mbrx-20231229_pre.xml" ] }, "inline": { "local": [ "mbrx20240104c_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.mbrx.com/20231229/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mbrx20240104c_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mbrx20240104c_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mbrx.com/20231229/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001437749-24-000758-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-000758-xbrl.zip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